Models of Physiology and Physiologically Based Models in Clinical Pharmacology

被引:9
|
作者
Atkinson, A. J., Jr. [1 ]
Smith, B. P. [2 ]
机构
[1] Northwestern Univ, Dept Mol Pharmacol & Biochem, Feinberg Sch Med, Chicago, IL 60611 USA
[2] Amgen Inc, Biostat Med Sci, Thousand Oaks, CA USA
关键词
KINETICS; CIRCULATION; PHARMACOKINETICS; HETEROGENEITY; AGENTS; BLOOD; FLOW;
D O I
10.1038/clpt.2012.67
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
As science matures, it becomes more mathematical, progressing from enumeration to the use of equations to the formulation of models. Clinical pharmacology has developed to the stage where models play an increasingly important role in predicting and analyzing drug pharmacokinetics and pharmacodynamics, and even in characterizing disease progression and therapeutic response. Useful models have two characteristics that are in ostensible conflict: (i) they must accurately represent the essential features of the underlying system and (ii) the representation must be sufficiently simplified to enable its salient features to be identified and investigated through further experimentation.
引用
收藏
页码:3 / 6
页数:4
相关论文
共 50 条
  • [21] An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery
    Parrott, N
    Paquereau, N
    Coassolo, P
    Lavé, T
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (10) : 2327 - 2343
  • [22] Reduction and Lumping of Physiologically Based Pharmacokinetic Models: Prediction of the Disposition of Fentanyl and Pethidine in Humans by Successively Simplified Models
    Sven Björkman
    Journal of Pharmacokinetics and Pharmacodynamics, 2003, 30 : 285 - 307
  • [23] Reduction and lumping of physiologically based pharmacokinetic models:: Prediction of the disposition of fentanyl and pethidine in humans by successively simplified models
    Björkman, S
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2003, 30 (04) : 285 - 307
  • [24] Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development
    Peterson, JK
    Houghton, PJ
    EUROPEAN JOURNAL OF CANCER, 2004, 40 (06) : 837 - 844
  • [25] A new generic approach to model reduction for complex physiologically based drug models
    Mahfouf, M
    Linkens, DA
    Xue, D
    CONTROL ENGINEERING PRACTICE, 2002, 10 (01) : 67 - 81
  • [26] The use of physiologically-based pharmacokinetic pharmacodynamic dosimetry models for chemical mixtures
    Yang, RSH
    ElMasri, HA
    Thomas, RS
    Constan, AA
    TOXICOLOGY LETTERS, 1995, 82-3 : 497 - 504
  • [27] Physiologically Based Construction of Optimized 3-D Arterial Tree Models
    Schneider, Matthias
    Hirsch, Sven
    Weber, Bruno
    Szekely, Gabor
    MEDICAL IMAGE COMPUTING AND COMPUTER-ASSISTED INTERVENTION, MICCAI 2011, PT I, 2011, 6891 : 404 - +
  • [28] Quantitative Comparison of Avian and Mammalian Physiologies for Parameterization of Physiologically Based Kinetic Models
    Scanes, Colin G.
    Witt, Johannes
    Ebeling, Markus
    Schaller, Stephan
    Baier, Vanessa
    Bone, Audrey J.
    Preuss, Thomas G.
    Heckmann, David
    FRONTIERS IN PHYSIOLOGY, 2022, 13
  • [29] Real-world application of physiologically based pharmacokinetic models in drug discovery
    Santos, Laura G. A.
    Jaiswal, Swati
    Chen, Kuan-Fu
    Jones, Hannah M.
    Templeton, Ian E.
    DRUG METABOLISM AND DISPOSITION, 2025, 53 (01)
  • [30] Framework for evaluation of physiologically-based pharmacokinetic models for use in safety or risk assessment
    Clark, LH
    Setzer, RW
    Barton, HA
    RISK ANALYSIS, 2004, 24 (06) : 1697 - 1717